Immunohistochemistry Market Size, Share, & Growth Report 2032
Meticulous Research®—a
leading global market research company, published a research report
titled Immunohistochemistry (IHC) Market Size, Share, Forecast, &
Trends Analysis by Offering (Reagents [Fixation, Buffer, Blocking, Antibodies],
Kits, Equipment [Staining, Imaging] Method (ABC, CSA, PAP) Process,
Application, End User—Global Forecast to 2032.
According to this
latest publication from Meticulous Research®, the global
immunohistochemistry market is estimated to reach $4.08
billion by 2032 at a CAGR of 7.2% from 2025 to 2031.The growth of this market can be attributed
to various factors, such as the rising prevalence of chronic diseases coupled
with the increasing geriatric population, increasing focus on rare diseases,
rising awareness regarding early disease diagnosis, increasing R&D
expenditure, growing demand for drug discovery & development, rising
prevalence of infectious diseases, and the rise in healthcare expenditure. Furthermore,
increasing inclination towards personalized medicine, advancements in genomics
and proteomics, and increasing automation in immunohistochemistry are expected
to offer growth opportunities. However, stringent technical requirements,
regulatory processes, and the availability of alternative technology are major
hindrances to the market’s growth.
Key Players
The key players
operating in the global immunohistochemistry market are F. Hoffmann-La Roche
Ltd (Switzerland), Danaher Corporation (U.S.), Agilent Technologies, Inc.
(U.S.), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (U.S.), Eagle
Biosciences, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S), Cell Signaling
Technology, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Bio SB Inc. (U.S.), Biocare
Medical, LLC. (U.S.), Bio-Genex Laboratories (U.S.), CANDOR Bioscience GmbH
(Germany), and Innovex Biosciences Inc. (U.S.).
Key Factors Driving
Immunohistochemistry Market Growth:
One of the primary
drivers behind the expanding IHC market is the rising
prevalence of chronic diseases such as cancer, diabetes,
cardiovascular disorders, and infectious diseases. With cancer
anticipated to remain a leading cause of mortality—causing
nearly 10 million deaths annually according to WHO—there is a
greater demand for sophisticated diagnostic approaches. IHC plays
a pivotal role by enabling accurate categorization
and prognosis of tumors based on protein markers,
accelerating precise treatment decisions.
In parallel, the aging
global population is fueling an increased incidence of
age-related illnesses, thereby magnifying the need for advanced
laboratory solutions such as IHC. Societal changes, including
increased tobacco and alcohol consumption, sedentary lifestyles, and
poor dietary habits, contribute significantly to the
growing burden of chronic diseases, further driving
market adoption.
Additionally,
pharmaceutical and biotechnology industries are ramping up R&D
expenditures to propel discovery and development of new drugs,
leveraging IHC as a critical research tool. The European Union, for
example, boosted R&D spending to USD 374.1 billion in 2022, reflecting
mounting investments across regions such as India and China.
This investment is expected to bolster the demand for
innovative IHC products and solutions in the coming years.
Most Recent Global
Market Size Estimates and Forecasts:
The global immunohistochemistry
market size reached USD 2.8 billion in 2024, with projections to soar to
approximately USD 4.08 billion by 2032, registering a Compound Annual Growth
Rate (CAGR) of 7.2% from 2025 to 2032. Some forecasts suggest even higher
growth, with estimates reaching up to USD 5.73 billion by 2035 at a 6.7% CAGR,
depending on methodology and segment focus. This expansion is attributed to
rising demand for personalized medicine, increasing healthcare expenditures,
and technological innovations in diagnostics.
When segmenting by
product offering, consumables—especially reagents and kits—are expected to
dominate, comprising nearly 68.4% of the market share by 2025. Method-wise, the
avidin-biotin complex technique will continue leading due to its high
sensitivity, reduced assay time, and efficient detection capabilities.
Market
Opportunities for Players and New Entrants:
For established
companies, opportunities abound in developing AI-driven IHC technologies that
streamline workflow, enhance analysis, and standardize reporting—key for
large-scale clinical adoption. Recent launches, such as Indica Labs’ Breast IHC
AI and Visiopharm A/S’s Ki67 algorithm, are revolutionizing biomarker
quantification and tumor cell classification in cancer diagnostics.
New entrants should
leverage the growing focus on personalized medicine and capitalize on the shift
towards multiplexed diagnostic platforms. Expanding product portfolios to cover
not only oncology but also neurology, infectious disease, and veterinary diagnostics
can open lucrative, under-served markets. Strategic partnerships with research
organizations, local hospitals, and academic institutions are essential for
market access and visibility in regions like Asia Pacific, where healthcare
transformation is rapid.
Download Sample
Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5967
Key questions
answered in the report:
- Which are the high-growth market segments
in terms of offerings, method, application, end user, and region/country?
- What was the historical market size for
immunohistochemistry globally?
- What are the market forecasts and
estimates for the period 2025–2032?
- What are the major drivers, restraints,
challenges, opportunities, and trends in the immunohistochemistry market?
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Comments
Post a Comment